Oppenheimer Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at $3.27.

Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Aquestive Therapeutics, and Dyne Therapeutics. According to TipRanks, Brisebois has an average return of -3.0% and a 37.18% success rate on recommended stocks.

Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.72, representing a 166.67% upside. In a report released on May 10, Leerink Partners also initiated coverage with a Buy rating on the stock with a $8.00 price target.

Based on Aquestive Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.21 million and a GAAP net loss of $8.11 million. In comparison, last year the company earned a revenue of $10.68 million and had a GAAP net loss of $12.35 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics (AQST) Company Description:

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.